Importantly, our retrospective observation revealed that 2 ICC patients with HBV infection and low PD1+ TILs had a good response to anti-PD1 immunotherapy, although these data needed to be further validated by future randomized controlled trials. The gene discussed is PDCD1; the disease is intrahepatic cholangiocarcinoma.